[CUSIP No. P8696W104 SCHEDULE 13G 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands 5 SOLE VOTING POWER NUMBER OF]
[CUSIP No. P8696W104 SCHEDULE 13G 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands 5 SOLE VOTING POWER NUMBER OF]
[SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Check the appropriate box: [_] Preliminary Proxy Statement [_] Confidential, for Use of the [X] Definitive Proxy Statement [_] Definitive Additional Materials [_] Soliciting Material under Rule 14a-12 Tianyin Pharmaceutical Co., Inc. Payment of Filing Fee (Check the appropriate box): [X] No fee required [_] Fee computed on table below per Exchange]
[SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Check the appropriate box: [_] Preliminary Proxy Statement [_] Confidential, for Use of the [X] Definitive Proxy Statement [_] Definitive Additional Materials [_] Soliciting Material under Rule 14a-12 Tianyin Pharmaceutical Co., Inc. Payment of Filing Fee (Check the appropriate box): [X] No fee required [_] Fee computed on table below per Exchange]
[February 25, 2011 Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the February 16, 2011 comment letter (the “Comment Letter”) to Mr. Ronghua]
[February 25, 2011 Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the February 16, 2011 comment letter (the “Comment Letter”) to Mr. Ronghua]
[February 25, 2011 Staff Accountant Division ofrporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide thempanys responses to the February 16, 2011mment letter (themment Letter) to Mr. Ronghua]
[February 25, 2011 Staff Accountant Division ofrporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide thempanys responses to the February 16, 2011mment letter (themment Letter) to Mr. Ronghua]
[TPI Reports Record Second Quarter Fiscal Year 2011 Financial Results February 14, 2011 CHENGDU, China, Feb. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011. Second quarter fiscal] [Tianyin Pharmaceutical, Inc. Second Quarter Fiscal Year 2011 Earnings Results February 15, 2011 Operator: Good morning, ladies and gentleman, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Inc. Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode, and following the presentation, instructions will be given for the question and answer session. Should] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT February 15, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 7 –]
[TPI Reports Record Second Quarter Fiscal Year 2011 Financial Results February 14, 2011 CHENGDU, China, Feb. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011. Second quarter fiscal] [Tianyin Pharmaceutical, Inc. Second Quarter Fiscal Year 2011 Earnings Results February 15, 2011 Operator: Good morning, ladies and gentleman, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Inc. Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode, and following the presentation, instructions will be given for the question and answer session. Should] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT February 15, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 7 –]
